content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on November 1, 2022</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>UNITED
  STATES<BR>
  SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">Form
  S-8</FONT></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">REGISTRATION STATEMENT<BR>
  UNDER<BR>
  THE SECURITIES ACT OF 1933</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">Waldencast
  plc</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Exact name of
  registrant as specified in its charter)</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%; font-weight: bold; text-align: center">Jersey</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; font-weight: bold; text-align: center">Not Applicable</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">(State or other jurisdiction of<BR> incorporation or organization)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: center">(I.R.S. Employer<BR> Identification No.)</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10 Bank Street, Suite 560</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>White Plains, NY</B></P></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; font-weight: bold; text-align: center">10606</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">(Address of principal executive offices)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: center">(Zip code)</TD></TR>
    </TABLE>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Milk Makeup LLC Appreciation Rights Plan</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Obagi Global Holdings Limited 2021 Stock Incentive
  Plan</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Waldencast plc 2022 Incentive Award Plan</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Waldencast plc Incentive Inducement Award
  Plan<BR>
  <FONT STYLE="font-weight: normal">(Full title of the plans)</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Michel Brousset</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Executive Officer</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">c/o Waldencast plc</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10 Bank Street, Suite 560</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">White Plains, NY 10606</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(917) 546-6828<BR>
  <FONT STYLE="font-weight: normal">(Name and address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Paul T. Schnell,
  Esq.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Gregg A. Noel,
  Esq.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Maxim O. Mayer-Cesiano,
  Esq.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Michael J. Schwartz,
  Esq.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Skadden, Arps,
  Slate, </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Meagher &amp;
  Flom LLP </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">One Manhattan
  West </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">New York, NY
  10001 </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Tel: 212-735-3000</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
  &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth
  company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 20%; text-align: left">Large accelerated filer</TD><TD STYLE="width: 52%">&#9744;</TD>
      <TD STYLE="width: 25%; text-align: left">Accelerated filer</TD><TD STYLE="text-align: right; width: 3%">&#9744;</TD>
      </TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Non-accelerated filer</TD><TD>&#9746;</TD>
      <TD STYLE="text-align: left">Smaller reporting company</TD><TD STYLE="text-align: right">&#9744;</TD>
      </TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Emerging growth company</TD><TD STYLE="text-align: right">&#9746;</TD>
      </TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate
  by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXPLANATORY NOTE</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Registration Statement on Form S-8
  (this &ldquo;Registration Statement&rdquo;) covers the registration of (i) 2,038,112 Class A ordinary shares, par value $0.0001 per
  share (&ldquo;Class A Ordinary Shares&rdquo;), of Waldencast plc., a Jersey public limited company (the &ldquo;Company&rdquo;)
  reserved for issuance under the Milk Makeup LLC Appreciation Rights Plan (the &ldquo;Milk Plan&rdquo;); (ii) 7,696,922 Class A
  Ordinary Shares of the Company reserved for issuance under the Obagi Global Holdings Limited 2021 Stock Incentive Plan (the
  &ldquo;Obagi Plan&rdquo;); (iii) 16,134,716 Class A Ordinary Shares of the Company reserved for issuance under the Waldencast plc
  2022 Incentive Award Plan (the &ldquo;Incentive Award Plan&rdquo;); and (iv) 950,000 Class A Ordinary Shares of the Registrant
  reserved for issuance under the Waldencast plc Incentive Inducement Award Plan (the &ldquo;Inducement Plan&rdquo; and together with
  the Milk Plan, the Obagi Plan and the Incentive Award Plan the &ldquo;Plans&rdquo;). The Incentive Award Plan has been approved by
  the Company&rsquo;s board of directors and shareholders. The Obagi Plan and the Milk Plan, along with the underlying outstanding
  equity awards (as converted in connection with the Business Combination) and the shares available for issuance under each such plan,
  have been approved and assumed by the Company&rsquo;s board of directors in connection with the closing of the business combination
  between the Company, Obagi Global Holdings Limited, a Cayman Islands exempted company limited by shares (&ldquo;Obagi&rdquo;), and
  Milk Makeup LLC, a Delaware limited liability company (&ldquo;Milk&rdquo;) (such transaction, the &ldquo;Business
  Combination&rdquo;). The Inducement Plan has been approved by the Company&rsquo;s board of directors and does not require
  shareholder approval because we are a foreign private issuer and the Inducement Plan provides for incentive awards to individuals,
  who satisfy the standards for &ldquo;employment inducement&rdquo; awards under Rule 5635(c)(4) of the Nasdaq Listing Rules, as an
  inducement material to such individuals&rsquo; entry into employment with the Company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Registration Statement includes a prospectus
  (the &ldquo;Reoffer Prospectus&rdquo;) prepared in accordance with General Instruction C of Form S-8. This Reoffer Prospectus may be used
  for the reoffer and resale of Class A Ordinary Shares on a continuous or delayed basis that may be deemed to be &ldquo;control securities&rdquo;
  within the meaning of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the rules and regulations promulgated
  thereunder, that are issuable to certain of our executive officers identified in the Reoffer Prospectus. The number of Class A Ordinary
  Shares included in the Reoffer Prospectus represents Class A Ordinary Shares issuable to the selling holders pursuant to the Plans and
  does not necessarily represent a present intention to sell any or all such Class A Ordinary Shares. The number of Class A Ordinary Shares
  to be offered or resold by means of the Reoffer Prospectus by each selling holder, and any other person with whom such holder is acting
  in concert for the purpose of selling Class A Ordinary Shares, may not exceed, during any three-month period, the amount specified in
  Rule 144(e) under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART I</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INFORMATION REQUIRED IN THE SECTION 10(A)
  PROSPECTUS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> Item 1. <I>Plan Information.</I></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The document(s) containing the information specified
  in Part I of this Registration Statement will be sent or given to the participants as specified by Rule 428(b)(1) of the Securities Act.
  Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), either
  as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These
  documents, and the documents incorporated by reference herein pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus
  that meets the requirements of Section 10(a) of the Securities Act.</P>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> Item 2. <I>Registrant Information and Employee Plan Annual Information</I>.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The written statement required by Item 2 of Part
  I is included in documents that will be delivered to participants in the plans covered by this Registration Statement pursuant to Rule
  428(b) of the Securities Act. In accordance with the rules and regulations of the SEC and the instructions to Form S-8, such documents
  are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to
  Rule 424 under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WALDENCAST PLC<BR>
  12,462,137 Class A Ordinary Shares Offered by Selling Holders</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This reoffer prospectus (&ldquo;Reoffer Prospectus&rdquo;)
  relates to the offer and sale from time to time by the selling holders named in this Reoffer Prospectus (the &ldquo;Selling Holders&rdquo;),
  or their permitted transferees, of up to 12,462,137 Class A ordinary shares, par value of $0.0001 per share (the &ldquo;Class A Ordinary
  Shares&rdquo;), of Waldencast plc., a Jersey public limited company (the &ldquo;Company&rdquo;). If, subsequent to the date of this Reoffer
  Prospectus, we grant or deliver additional Class A Ordinary Shares to the Selling Holders or to other affiliates under the Plans, we may
  supplement this Reoffer Prospectus to reflect such additional shares to the Selling Holders and/or the names of such affiliates and the
  number of shares to be reoffered by them under the Plans. We are not offering any Class A Ordinary Shares and will not receive any proceeds
  from the sale of Class A Ordinary Shares by the Selling Holders pursuant to this Reoffer Prospectus. The Selling Holders are certain of
  our executive officers, each of whom may be considered an &ldquo;affiliate&rdquo; of our company (as defined in Rule 405 under the Securities
  Act of 1933, as amended (the &ldquo;Securities Act&rdquo;)).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the satisfaction of any conditions
  to vesting of the Class A Ordinary Shares offered hereby pursuant to the terms of the relevant award agreements and the applicable Plan,
  the Selling Holders may from time to time sell, transfer or otherwise dispose of any or all of the Class A Ordinary Shares covered by
  this Reoffer Prospectus through underwriters or dealers, directly to purchasers (or a single purchaser) or through broker-dealers or agents.
  If underwriters or dealers are used to sell the Class A Ordinary Shares, we will name them and describe their compensation in a prospectus
  supplement. The Class A Ordinary Shares may be sold in one or more transactions at fixed prices, prevailing market prices at the time
  of sale, prices related to the prevailing market prices, varying prices determined at the time of sale or negotiated prices. We do not
  know when or in what amount the Selling Holders may offer Class A Ordinary Shares for sale. The Selling Holders may sell any, all or none
  of the Class A Ordinary Shares offered by this Reoffer Prospectus. See &ldquo;<I>Plan of Distribution</I>&rdquo; beginning on page 5
  for more information about how the Selling Holders may sell or dispose of the Class A Ordinary Shares covered by this Reoffer Prospectus.
  The Selling Holders will bear all sales commissions and similar expenses. We will bear all expenses of registration incurred in connection
  with this offering, including any other expenses incurred by us in connection with the registration and offering that are not borne by
  the Selling Holders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Class A Ordinary Shares that will be issued
  pursuant to restricted stock units, stock appreciation rights and stock options granted to Selling Holders will be &ldquo;control securities&rdquo;
  under the Securities Act before their sale under this Reoffer Prospectus. This Reoffer Prospectus has been prepared for the purposes of
  registering the Class A Ordinary Shares under the Securities Act to allow for future sales by Selling Holders on a continuous or delayed
  basis to the public without restriction, provided that the number of Class A Ordinary Shares to be offered or resold under this Reoffer
  Prospectus by each Selling Holder or other person with whom he, she or they are acting in concert for the purpose of selling Class A Ordinary
  Shares, may not exceed, during any three-month period, the amount specified in Rule 144(e) under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our Class A Ordinary Shares are currently listed on
  The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;WALD.&rdquo; On October 31, 2022, the last reported sales price
  of the Class A Ordinary Shares on Nasdaq was $8.90 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>We are an &ldquo;emerging growth company,&rdquo;
  as defined under the federal securities laws, and, as such, have elected to comply with certain reduced public company reporting requirements
  for this Reoffer Prospectus and for future filings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS
  THAT ARE DESCRIBED IN THE &ldquo;RISK FACTORS&rdquo; SECTION BEGINNING ON PAGE 3 OF THIS REOFFER PROSPECTUS, AND SUCH RISKS AND THE
  &ldquo;CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS&rdquo; ON PAGE v OF THIS REOFFER PROSPECTUS SHOULD BE REVIEWED CAREFULLY.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Neither the Securities and Exchange Commission
  nor any state securities commission has approved or disapproved of the securities to be issued under this Reoffer Prospectus or determined
  if this Reoffer Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The date of this Reoffer Prospectus is November
  1, 2022</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 91%; font-size: 10pt; text-align: left"><A HREF="#a_001">ABOUT THIS REOFFER PROSPECTUS</A></TD>
      <TD STYLE="width: 9%; font-size: 10pt; text-align: center">ii</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_002">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">iii</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_003">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">iv</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_004">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">v</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_005">SUMMARY OF THE PROSPECTUS</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">1</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_006">RISK FACTORS</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">3</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_007">DETERMINATION OF OFFERING PRICE</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">3</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_008">USE OF PROCEEDS</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">3</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_009">SELLING HOLDERS</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">4</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_010">PLAN OF DISTRIBUTION</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">5</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_011">LEGAL MATTERS</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">6</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_012">EXPERTS</A></TD>
      <TD STYLE="font-size: 10pt; text-align: center">6</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.95pt"><B>You should rely only on the information contained
  in this Reoffer Prospectus. No one has been authorized to provide you with information that is different from that contained in this Reoffer
  Prospectus. If anyone provides you with different or inconsistent information, you should not rely on it.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.95pt"><B>For investors outside the United States:&nbsp;</B>We
  have not done anything that would permit this offering or possession or distribution of this Reoffer Prospectus in any jurisdiction where
  action for that purpose is required, other than in the United States. You are required to inform yourselves about, and to observe, any
  restrictions relating to this offering and the distribution of this Reoffer Prospectus.<FONT STYLE="text-transform: uppercase"><B></B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  
  <!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_001"></A>ABOUT
  THIS REOFFER PROSPECTUS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Reoffer Prospectus contains important information
  you should know before investing, including important information about the Company and the securities being offered. You should carefully
  read this Reoffer Prospectus, as well as the additional information contained in the documents described under &ldquo;<I>Where You Can
  Find More Information</I>&rdquo; and &ldquo;<I>Incorporation of Certain Information by Reference</I>&rdquo; in this Reoffer Prospectus,
  and in particular the periodic and current reporting documents we file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).
  This Reoffer Prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction
  where the offer or sale is not permitted.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Reoffer Prospectus is dated as of the date
  set forth on the cover hereof. You should not assume that the information contained in this Reoffer Prospectus is accurate as of any date
  other than that date or as of any earlier date specified, including in any information incorporated by reference. Our business, financial
  condition, results of operations and prospects may have changed since those dates.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Jersey Financial Services Commission (&ldquo;JFSC&rdquo;)
  has given and has not withdrawn, its consent under Article 4 of the Control of Borrowing (Jersey) Order 1958 to the issue of securities
  in the Issuer. The JFSC is protected by the Control of Borrowing (Jersey) Law 1947, as amended, against liability arising from the discharge
  of its functions under that Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A copy of this prospectus has been delivered to
  the Jersey Registrar of Companies (the &ldquo;Jersey Registrar&rdquo;) in accordance with Article 5 of the Companies (General Provisions)
  (Jersey) Order 2002 and the Jersey Registrar has given, and has not withdrawn, his consent to its circulation. It must be distinctly understood
  that, in giving these consents, neither the Jersey Registrar nor the JFSC takes any responsibility for the financial soundness of the
  Company or for the correctness of any statements made, or opinions expressed, with regard to it. The JFSC is protected by the Control
  of Borrowing (Jersey) Law 1947, as amended, against liability arising from the discharge of its functions under that law. The directors
  of the Company have taken all reasonable care to ensure that the facts stated in this prospectus are true and accurate in all material
  respects, and that there are no other facts the omission of which would make misleading any statement in the document, whether or facts
  or of opinion. The directors accept responsibility accordingly. It should be remembered that the price of securities and the income from
  them can go down as well as up. If you are in any doubt about the contents of this prospectus, you should consult your stockbroker, bank
  manager, solicitor, accountant or financial adviser.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_002"></A>WHERE
  YOU CAN FIND MORE INFORMATION</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have filed a Registration Statement on Form
  S-8 (this &ldquo;Registration Statement&rdquo;), including exhibits, under the Securities Act, with respect to the Class A Ordinary Shares
  offered by this Reoffer Prospectus. This Reoffer Prospectus does not contain all of the information included in this Registration Statement.
  For further information pertaining to us and our securities, you should refer to this Registration Statement and its exhibits.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are subject to the informational requirements
  of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) that are applicable to foreign private issuers. Accordingly,
  we are required to file or furnish reports and other information with the SEC, including annual reports on Form 20-F and reports on Form
  6-K. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with
  the SEC. Our filings with the SEC are available to the public through the SEC&rsquo;s website at http://www.sec.gov.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a foreign private issuer, we are exempt under
  the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers,
  directors and principal and Selling Securityholders are exempt from the reporting and short-swing profit recovery provisions contained
  in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial
  statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We maintain a corporate website at www.waldencast.com.
  Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included
  our website address in this prospectus solely for informational purposes.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_003"></A>INCORPORATION
  OF CERTAIN INFORMATION BY REFERENCE</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following documents, previously filed by the
  Company with the SEC, are incorporated by reference in this Registration Statement of which this Reoffer Prospectus forms a part:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>The Company&rsquo;s prospectus relating to the Registration Statement on Form F-1, as amended (File No. 333-267053), filed with the
  SEC under Rule <A HREF="http://www.sec.gov/Archives/edgar/data/1840199/000121390022063843/ea166952-424b3_waldencastplc.htm">424(b)</A> under the Securities Act on October 13, 2022, which contains, inter alia, the audited financial statements of the
  Company for the latest fiscal year for which such statements have been filed; and</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                             </TABLE>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of the Company&rsquo;s Class A Ordinary Shares contained in the Company&rsquo;s Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1840199/000114036122005047/ny20001615x3_f4.htm">Form F-4</A>, as amended (File No. 333-262692) filed with the SEC on February 14, 2022, including any amendments or reports filed for the purpose of updating such description.</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All reports and other documents subsequently filed
  by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement of which
  this Reoffer Prospectus forms a part, but prior to the filing of a post-effective amendment which indicates that all securities offered
  hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein
  and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been
  furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Reoffer Prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any statement contained herein or in a document,
  all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this Reoffer Prospectus to the extent that a statement contained herein or in any other subsequently filed document which
  also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute a part of this Reoffer Prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company undertakes to provide without charge
  to each person, including any beneficial owner, to whom a copy of this Reoffer Prospectus is delivered, upon written or oral request of
  any such person, a copy of any and all of the information that has been incorporated by reference in this Reoffer Prospectus but not delivered
  with this Reoffer Prospectus other than the exhibits to those documents, unless the exhibits are specifically incorporated by reference
  into the information that this Reoffer Prospectus incorporates. Documents incorporated by reference in this Reoffer Prospectus may be
  obtained by requesting them in writing or by telephone from us at:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Waldencast plc</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10 Bank Street, Suite 560</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">White Plains, NY 10606</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (917) 546-6828</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_004"></A>CAUTIONARY
  STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain statements made in this Reoffer Prospectus
  are &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act,
  and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements
  provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations,
  beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words such as &ldquo;estimates,&rdquo;
  &ldquo;projected,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimated,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;projects,&rdquo;
  &ldquo;forecasts,&rdquo; &ldquo;plans,&rdquo; &ldquo;intends,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
  &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;future,&rdquo; &ldquo;propose,&rdquo; &ldquo;target,&rdquo; &ldquo;goal,&rdquo;
  &ldquo;objective,&rdquo; &ldquo;outlook&rdquo; and variations of these words or similar expressions (or the negative versions of such
  words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future
  performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors,
  many of which are outside our control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
  statements. Important factors, among others, that may affect actual results or outcomes include:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our inability to recognize the anticipated benefits of the transactions with Obagi and Milk;</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                 </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>changes in general economic conditions, including as a result of the COVID-19 pandemic;</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                            </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to continue to meet Nasdaq&rsquo;s listing standards;</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                      </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>volatility of our securities due to a variety of factors, including our inability to meet or exceed our financial projections and
  changes;</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                    </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities;</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                   </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to implement strategic initiatives and continue to innovate Obagi&rsquo;s and Milk&rsquo;s existing products and anticipate
  and respond to market trends and changes in consumer preferences; and</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                 </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>other factors detailed in the section entitled &ldquo;Risk Factors.&rdquo;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The forward-looking statements contained in this
  Reoffer Prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us.
  There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements
  involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or
  performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties
  include, but are not limited to, those factors described under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this Reoffer Prospectus.
  Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary
  in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking
  statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities
  laws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid; width: 98%">
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: none"><A NAME="a_005"></A>SUMMARY
  OF THE PROSPECTUS</FONT></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>This Reoffer Prospectus is part of this Registration
  Statement that we filed with the SEC. We have provided to you in this Reoffer Prospectus a general description of the Selling Holders
  and the distribution of the Class A Ordinary Shares. To the extent there is a conflict between the information contained in this Reoffer
  Prospectus and any of our subsequent filings with the SEC, the information in the document having the later date shall modify or supersede
  the earlier statement.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>As permitted by the rules and regulations of
  the SEC, this Registration Statement of which this Reoffer Prospectus forms a part includes additional information not contained in this
  Reoffer Prospectus. You may read this Registration Statement and the other reports we file with the SEC at the SEC&rsquo;s website or
  at our website as described above under the heading &ldquo;Incorporation of Certain Information by Reference.&rdquo;</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>As used in this Reoffer Prospectus, unless
  the context otherwise requires or indicates, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and the &ldquo;Company&rdquo;
  refer to Waldencast plc and its consolidated subsidiaries.</I></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Company Overview</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Founded by Michel Brousset and Hind Sebti, our
  ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling
  conscious, high-growth purpose-driven brands. Our vision is fundamentally underpinned by our brand-led business model that ensures proximity
  to our customers, business agility and market responsiveness, while maintaining each brand&rsquo;s distinct DNA. The first step in realizing
  our vision was the business combination with Obagi and Milk. As part of the Waldencast platform, our brands will benefit from the operational
  scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations;
  asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We were incorporated on December 8, 2020 as a
  Cayman Islands exempted company and a blank check company solely for the purpose of effecting the Business Combination, which was consummated
  on July 27, 2022. On July 26, 2022, with the approval of our shareholders, and in accordance with the Cayman Act, the Jersey Companies
  Law and our memorandum and articles of association, we effected a domestication, pursuant to which our jurisdiction of incorporation was
  changed from the Cayman Islands to Jersey and our name was changed from Waldencast Acquisition Corp. to Waldencast plc, a public limited
  company incorporated under the laws of Jersey. Upon the closing of the Business Combination, we acquired the businesses of Obagi and Milk,
  which are now indirect subsidiaries of Waldencast.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Our Professional Skincare Segment: Obagi</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our professional skincare segment consists of
  the Obagi business. Obagi is currently headquartered in Long Beach, California, but will begin operating out of new headquarters in Houston,
  Texas in the fourth quarter of 2022. Obagi is a pioneer of the professional skincare category and its products are rooted in research
  and skin biology. Obagi develops, markets and sells innovative skin health products in more than 60 countries around the world. The Obagi&reg;
  collection of products includes the following brands, with more than 200 products sold throughout the medical, spa and retail channels:
  Obagi Medical&reg;, Obagi Clinical&reg; and Skintrinsiq&trade;. While the product portfolio consists predominantly of cosmetic and over-the-counter
  (&ldquo;OTC&rdquo;) drug products, Obagi does offer prescription-strength drug products, which require approval from the U.S. Food and
  Drug Administration (the &ldquo;FDA&rdquo;) prior to marketing. We have not sought or obtained FDA pre-market approval or foreign regulatory
  authorities&rsquo; authorization for any Obagi products, including the Skintrinsiq device, which we believe does not require marketing
  authorization from the FDA. These prescription-strength products include the Obagi Nu-Derm&reg; System and related products, some of which
  contain a 4% concentration of the ingredient hydroquinone (&ldquo;HQ&rdquo;). These products are marketed as prescription-use only drugs
  but have not received marketing authorization from the FDA or other regulatory authorities. The FDA has historically utilized a risk-based
  enforcement approach with respect to drugs marketed without the required New Drug Application (&ldquo;NDA&rdquo;) in accordance with a
  Compliance Policy Guide (&ldquo;CPG&rdquo;) it issued in 2006 and subsequently amended in 2011, in which the FDA announced a drug safety
  initiative to remove unapproved drugs from the market, and established enforcement priorities and a policy of enforcement discretion with
  respect to marketed unapproved products. We believe Obagi&rsquo;s prescription-only HQ products do not fall within the categories of unapproved
  drugs for which the FDA has indicated it prioritizes enforcement. We have not received any communications from the FDA or any similar
  regulatory authorities regarding its HQ or any of its other products. However, whether due to safety concerns or otherwise, in the future
  the FDA may choose to pursue an enforcement action against us and determine that Obagi HQ products should be removed from the market until
  we obtain FDA approval of the required NDA. Although Obagi prescription-only HQ products are made with 4% HQ, the FDA has historically
  expressed concerns regarding the safety of 2% HQ products sold on an OTC basis. In addition, the CARES Act implemented a number of changes
  to regulation of OTC drugs, one of which prohibited the sale of HQ (at any concentration level) from being marked in the U.S. as an OTC
  drug without FDA approval effective September 2020. On April 19, 2022, the FDA announced that it had issued warning letters to 12 companies
  for continuing to sell 2% HQ products on an OTC basis in violation of the CARES Act. The FDA&rsquo;s announcement also cited reports describing
  serious side effects associated with the use of skin lightening products containing HQ, including reports of skin rashes, facial swelling,
  and ochronosis (discoloration of the skin). The FDA&rsquo;s safety concerns regarding these lower-concentration OTC HQ products could
  prompt the FDA to assert that Obagi&rsquo;s higher-concentration, prescription-only HQ products represent a higher priority for enforcement
  pursuant to the active CPG. In addition, Obagi&rsquo;s prescription-only products are not currently available in pharmacies. Certain states,
  including Massachusetts, Montana, New Hampshire, New York and Texas, prohibit physicians from dispensing prescription products without
  a pharmacy or other license or authorization, permitting dispensing of such products only in certain limited circumstances. For these
  states we offer alternate products under our Obagi Nu-Derm Fx&reg; and Obagi-C&reg; Fx product lines that contain the skin brightening
  ingredient arbutin rather than 4% HQ. Further, we are aware that the state of Texas and Puerto Rico, as well as certain credit card authorization
  vendors, have taken action against physician customers who sell Obagi&rsquo;s prescription products to patients over the Internet. Most
  of these physicians ceased selling the prescription products online, offering them only in office to patients, and/or chose to sell Obagi&rsquo;s
  alternate arbutin products online instead. These actions have not had a material impact on our or Obagi&rsquo;s sales or net revenue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>
  
  <!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid; width: 98%">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Our &ldquo;Clean&rdquo; Makeup Segment: Milk</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our &ldquo;clean&rdquo; makeup segment consists
  of the Milk business. Milk is a leading, award-winning clean prestige makeup brand with unique products, a dedicated following among Gen-Z
  consumers and an emerging global presence. Milk has achieved significant growth thus far but believes even more significant growth opportunities
  remain in terms of building awareness, product and category expansion, channel expansion and regional expansion.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that Milk&rsquo;s inclusive brand values,
  &ldquo;clean&rdquo; product philosophy and commitments to sustainability and philanthropy are at the zeitgeist of what will motivate the
  next generation of beauty consumers around the world, and that these values and product attributes will only become more relevant. We
  believe that Milk&rsquo;s ability to authentically connect with youth culture while developing unique, effective and easy to use products
  that are also 100% vegan, clean and cruelty-free sets Milk apart from other brands.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Milk was launched in 2016 with the goal of building
  a global movement to challenge and broaden the definition of beauty. Community and self-expression are at the heart of everything Milk
  does, believing that it&rsquo;s not how you wear your makeup, it&rsquo;s what you do in it that matters. This ethos is captured in Milk&rsquo;s
  brand signature, &ldquo;Live Your Look.&rdquo;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Offering</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Reoffer Prospectus relates to the offer and
  sale from time to time by the Selling Holders, or their permitted transferees, of up to 12,462,137 Class A Ordinary Shares. If, subsequent
  to the date of this Reoffer Prospectus, we grant additional Class A Ordinary Shares to the Selling Holders or to other affiliates under
  the Plans, we may supplement this Reoffer Prospectus to reflect such additional shares to the Selling Holders and/or the names of such
  affiliates and the number of shares to be reoffered by them under the Plans. Subject to the satisfaction of any conditions to vesting
  of the Class A Ordinary Shares offered hereby pursuant to the terms of the relevant award agreements, the Selling Holders may from time
  to time sell, transfer or otherwise dispose of any or all of the Class A Ordinary Shares covered by this Reoffer Prospectus through underwriters
  or dealers, directly to purchasers (or a single purchaser) or through broker-dealers or agents. We will not receive any proceeds from
  the sale of Class A Ordinary Shares by the Selling Holders. The Selling Holders will bear all sales commissions and similar expenses.
  We will bear all expenses of registration incurred in connection with this offering, including any other expenses incurred by us in connection
  with the registration and offering that are not borne by the Selling Holders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  </DIV>
  
  
  <!-- Field: Page; Sequence: 11; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_006"></A>RISK
  FACTORS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Investing in Class A Ordinary Shares involves
  a high degree of risk. Investors should carefully consider the risks we have described under &ldquo;Risk Factors&rdquo; in our prospectus
  relating to the Registration Statement on Form F-1, as amended (File No. 333-267053), filed with the SEC under Rule <A HREF="https://www.sec.gov/Archives/edgar/data/1840199/000121390022063843/ea166952-424b3_waldencastplc.htm" STYLE="-sec-extract: exhibit">424(b)</A> under the Securities
  Act on October 13, 2022, together with all the other information appearing in or incorporated by reference into this Reoffer Prospectus,
  before deciding to invest in our Class A Ordinary Shares. If any of the events or developments we have described occur, our business,
  financial condition, or results of operations could be materially or adversely affected. As a result, the market price of our Class A
  Ordinary Shares could decline, and investors could lose all or part of their investment. The risks and uncertainties we have described
  are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that we currently
  deem immaterial may also impair our business operations. The risks we have described also include forward-looking statements, and our
  actual results may differ substantially from those discussed in these forward-looking statements. See &ldquo;<I>Cautionary Statement Regarding
  Forward-Looking Statements</I>.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_007"></A>DETERMINATION
  OF OFFERING PRICE</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Holders will determine at what price
  they may sell the offered Class A Ordinary Shares, and such sales may be made at prevailing market prices or at privately negotiated prices.
  See &ldquo;<I>Plan of Distribution</I>&rdquo; below for more information.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_008"></A>USE
  OF PROCEEDS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will not receive any proceeds from the sale
  of the Class A Ordinary Shares by the Selling Holders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 12; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_009"></A>SELLING
  HOLDERS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below sets forth information concerning
  the resale of the Class A Ordinary Shares by the Selling Holders. We will not receive any proceeds from the resale of the Class A Ordinary
  Shares by the Selling Holders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below sets forth, as of October 1,
  2022 (the &ldquo;Determination Date&rdquo;): (i) the name of each person who is offering the resale of Class A Ordinary Shares by this
  Reoffer Prospectus; (ii) the number of Class A Ordinary Shares that each Selling Holder may offer for sale from time to time pursuant
  to this Reoffer Prospectus, whether or not such Selling Holder has a present intention to do so; and (iii) the number (and the percentage,
  if 1% or more) of Class A Ordinary Shares each person will own after the offering, assuming they sell all of the shares offered. Unless
  otherwise indicated, beneficial ownership is direct and the person indicated has sole voting and investment power. Unless otherwise indicated,
  the address for each Selling Holder listed in the table below is c/o Waldencast plc., 10 Bank Street, Suite 560, White Plains, NY 10606.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Holders identified below may have
  sold, transferred or otherwise disposed of some or all of their Class A Ordinary Shares since the date on which the information in the
  following table is presented in transactions exempt from or not subject to the registration requirements of the Securities Act. Information
  concerning the Selling Holders may change from time to time and, if necessary, we will amend or supplement this Reoffer Prospectus accordingly.
  We cannot give an estimate as to the number of Class A Ordinary Shares that will actually be held by the Selling Holders upon termination
  of this offering because the Selling Holders may offer some or all of their Class A Ordinary Shares under the offering contemplated by
  this Reoffer Prospectus or acquire additional Class A Ordinary Shares. The total number of Class A Ordinary Shares that may be sold hereunder
  will not exceed the number of Class A Ordinary Shares offered hereby. Please read the section entitled &ldquo;<I>Plan of Distribution</I>&rdquo;
  in this Reoffer Prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Selling
      Holder</B></FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Position
      with Company</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Class
      A Ordinary Shares Beneficially Owned Prior<BR> to this <BR> Offering&nbsp;(1)&nbsp;(2)</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Class
      A Ordinary Shares Offered for Resale<BR> in this<BR> Offering&nbsp;(2)</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Class
      A Ordinary Shares Beneficially Owned <BR> After this<BR> Offering&nbsp;(3)</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Percentage<BR>
  
      of Class A<BR>
   Ordinary<BR>
   Shares<BR>
   Beneficially<BR>
   Owned<BR> After this<BR> Offering&nbsp;(1)(3)</FONT></TD>
      <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; width: 20%; text-align: left">Michel Brousset<FONT STYLE="font-size: 10pt"><B><SUP>(4)</SUP></B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 39%; text-align: center">Chief Executive Officer and Director</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 7%; text-align: right">14,109,447</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 7%; text-align: right">8,950,000</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 7%; text-align: right">5,159,447</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 7%; text-align: right">5.8</TD>
      <TD STYLE="width: 1%; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Hind Sebti</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">Chief Growth Officer</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: right">3,502,000</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: right">3,502,000</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: right">&mdash;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: right">&mdash;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Philippe Gautier</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">Chief Financial Officer and<BR>
   Chief Operating Officer</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: right">10,137</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: right">10,137</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: right">&mdash;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: right">&mdash;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">*</TD><TD>Less than 1%</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(1)</TD><TD>Beneficial ownership and the percentage of Class A Ordinary Shares beneficially owned is computed on the basis of 86,460,560 Class
  A Ordinary Shares outstanding as of the Determination Date and determined in accordance with the rules and regulations of the SEC.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(2)</TD><TD>Includes Class A Ordinary Shares issuable upon settlement of restricted stock units and stock options, including those that will vest
  more than 60 days from the Determination Date.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)</P></TD>
      <TD STYLE="text-align: justify">Assumes that all of the Class A Ordinary Shares held by each Selling Holder and being offered under this Reoffer Prospectus are sold, and that no Selling Holder will acquire additional Class A Ordinary Shares before the completion of this offering.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(4)</TD>
      <TD STYLE="text-align: justify">Includes (i) 2,848,334 Class A ordinary shares, (ii) 1,977,779 Class A ordinary shares issuable upon exercise of the private placement warrants and (iii) 333,334 Class A ordinary shares issuable upon exercise of the working capital loan warrants, held by Waldencast Ventures, LP. Mr. Brousset is the chief executive officer of Waldencast Management, LLC, the general partner of Waldencast Ventures, LP. As such, he may be deemed to beneficially own the shares held by Waldencast Ventures, LP.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in"></P>
  
  <!-- Field: Page; Sequence: 13; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_010"></A>PLAN
  OF DISTRIBUTION</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Class A Ordinary Shares covered by this Reoffer
  Prospectus are being registered by the Company for the account of the Selling Holders. The Class A Ordinary Shares offered may be sold
  from time to time directly by or on behalf of each Selling Holder in one or more transactions on Nasdaq or any other stock exchange on
  which the Class A Ordinary Shares may be listed at the time of sale, in privately negotiated transactions, or through a combination of
  such methods, at market prices prevailing at the time of sale, at prices related to such prevailing market prices, at fixed prices (which
  may be changed) or at negotiated prices. The Selling Holders may from time to time sell, transfer or otherwise dispose of any or all of
  the Class A Ordinary Shares covered by this Reoffer Prospectus through underwriters or dealers, directly to purchasers (or a single purchaser)
  or through broker-dealers or agents. Such underwriters or dealers may receive compensation in the form of commissions, discounts or concessions
  from the Selling Holders and/or purchasers of the shares or both. Such compensation as to a particular underwriter, broker or dealer may
  be in excess of customary commissions. The number of Class A Ordinary Shares to be reoffered or resold under the Reoffer Prospectus by
  each Selling Holder and any other person with whom he, she or they is acting in concert for the purpose of selling Class A Ordinary Shares,
  may not exceed, during any three-month period, the amount specified in Rule 144(e) under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with their sales, a Selling Holder
  and any participating underwriter or dealer may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act, and
  any commissions they receive and the proceeds of any sale of shares may be deemed to be underwriting discounts and commissions under the
  Securities Act. We are bearing all costs relating to the registration of the Class A Ordinary Shares. Any commissions or other fees payable
  to underwriters or dealers in connection with any sale of the shares will be borne by the Selling Holders or other party selling such
  shares. Sales of the Class A Ordinary Shares must be made by the Selling Holders in compliance with all applicable state and federal securities
  laws and regulations, including the Securities Act. In addition to any shares sold hereunder, Selling Holders may sell Class A Ordinary
  Shares in compliance with Rule 144, if available. There is no assurance that the Selling Holders will sell all or a portion of the Class
  A Ordinary Shares offered hereby. The Selling Holders may agree to indemnify any underwriter, broker, dealer or agent that participates
  in transactions involving sales of the Class A Ordinary Shares against certain liabilities in connection with the offering of the Class
  A Ordinary Shares arising under the Securities Act. We have notified the Selling Holders of the need to deliver a copy of this Reoffer
  Prospectus in connection with any sale of the Class A Ordinary Shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The anti-manipulation rules of Regulation M under
  the Exchange Act may apply to sales of Class A Ordinary Shares and activities of the Selling Holders, which may limit the timing of purchases
  and sales of any of the Class A Ordinary Shares by the Selling Holders and any other participating person. Regulation M may also restrict
  the ability of any person engaged in the distribution of the Class A Ordinary Shares to engage in passive market-making activities with
  respect to the Class A Ordinary Shares. Passive market making involves transactions in which a market maker acts as both our underwriter
  and as a purchaser of Class A Ordinary Shares in the secondary market. All of the foregoing may affect the marketability of the Class
  A Ordinary Shares and the ability of any person or entity to engage in market-making activities with respect to the Class A Ordinary Shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Once sold under the registration statement of
  which this Reoffer Prospectus forms a part, the Class A Ordinary Shares will be freely tradable in the hands of persons other than our
  affiliates.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 14; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_011"></A>LEGAL
  MATTERS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The validity of the securities offered hereby
  will be passed upon for us by Maples and Calder (Jersey) LLP, Jersey counsel to the Company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_012"></A>EXPERTS</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements of Waldencast Acquisition
  Corp. as of December 31, 2021 and 2020, and for the year ended December 31, 2021 and for the period from December 8, 2020 (inception)
  through December 31, 2020, incorporated by reference in this prospectus have been audited by Marcum LLP, an independent registered public
  accounting firm, as stated in their report incorporated by reference herein, which includes an explanatory paragraph as to the company&rsquo;s
  ability to continue as a going concern. Such financial statements are incorporated by reference in reliance upon the report of such firm
  given upon their authority as experts in accounting and auditing.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The consolidated financial statements of Obagi
  Global Holdings Limited as of December 31, 2021 and December 31, 2020 and for each of the three years in the period ended December 31,
  2021 incorporated by reference in this prospectus, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting
  firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given
  their authority as experts in accounting and auditing.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements of Milk Makeup LLC as
  of December 31, 2021, 2020 and 2019, and for each of the three years then ended incorporated by reference in this prospectus have been
  incorporated by reference herein in reliance upon the report of WithumSmith+Brown, PC, independent registered public accounting firm,
  incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 15; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A>PART II</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">Item 3.</TD><TD><I>Incorporation of Documents by Reference</I>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following documents, previously filed by the
  Company with the SEC, are incorporated by reference in this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>The Company&rsquo;s prospectus relating to the Registration Statement on Form F-1, as amended (File No. 333-267053), filed with the
  SEC under Rule <A HREF="http://www.sec.gov/Archives/edgar/data/1840199/000121390022063843/ea166952-424b3_waldencastplc.htm">424(b)</A> under the Securities Act on October 13, 2022, which contains, inter alia, the audited financial statements of the
  Company for the latest fiscal year for which such statements have been filed; and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of the Company&rsquo;s Class A Ordinary Shares contained in the Company&rsquo;s Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1840199/000114036122005047/ny20001615x3_f4.htm" STYLE="-sec-extract: exhibit">Form F-4</A>, as amended (File No. 333-262692) filed with the SEC on February 14, 2022, including any amendments or reports filed for the purpose of updating such description.</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All reports and other documents filed by the Company
  pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of this Registration Statement, but prior to the filing
  of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then
  remaining unsold, shall be deemed to be incorporated by reference in herein and to be a part hereof from the date of filing of such documents;
  provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall
  not be deemed incorporated by reference into this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any statement contained herein or in a document,
  all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded
  for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document
  which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified
  or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">Item 4.</TD><TD><I>Description of Securities</I>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">Item 5.</TD><TD><I>Interests of Named Experts and Counsel</I>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">Item 6.</TD><TD><I>Indemnification of Directors and Officers</I>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the Jersey
  Companies Law, our articles of association (the &ldquo;Articles&rdquo;) permit us (to the fullest extent permitted by the Jersey Companies
  Law to indemnify any director against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses,
  which they may incur as a result of any act or failure to act in carrying out their functions. However this does not apply if such liability
  incurred by reason of their own actual fraud, willful neglect or willful default. Subject to the Jersey Companies Law, our Articles also
  permit us to purchase and maintain insurance against any liability for any director and to provide any director with funds (whether by
  loan or otherwise) to meet expenditure incurred or to be incurred by him in defending any criminal, regulatory or civil proceedings or
  in connection with an application for relief (or to enable any such director to avoid incurring such expenditure).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">However, Article 77 of
  the Jersey Companies Law limits the ability of a Jersey company to exempt or indemnify a director from any liability arising from acting
  as a director. It provides that neither a company (or any of its subsidiaries) nor any other person for some benefit conferred or detriment
  suffered directly or indirectly by the company, may exempt or indemnify any director from, or against, any liability incurred by him as
  a result of being a director of the company except where the company exempts or indemnifies him against:</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD>any liabilities incurred in defending any proceedings (whether civil or criminal):</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">i)</TD><TD>in which judgment is given in his or her favor or he or she is acquitted;</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">ii)</TD><TD>which are discontinued otherwise than for some benefit conferred by him or her or on his or her behalf or some detriment suffered
  by him or her; or</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">iii)</TD><TD>which are settled on terms which include such benefit or detriment and, in the opinion of a majority of the directors of the company
  (excluding any director who conferred such benefit or on whose behalf such benefit was conferred or who suffered such detriment), he or
  she was substantially successful on the merits in his or her resistance to the proceedings; or</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>any liability incurred otherwise than to the company if he or she acted in good faith with a view to the best interests of the company;</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD>any liability incurred in connection with an application made under Article 212 of the Jersey Companies Law in which relief is granted
  to him or her by the court; or</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD>any liability against which the company normally maintains insurance for persons other than directors.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Article 77 of the Jersey Companies Law does not
  prevent a company from purchasing and maintaining directors&rsquo; and officers&rsquo; insurance and we maintain a directors&rsquo; and
  officers&rsquo; liability insurance policy for the benefit of our directors and officers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">Item 7.</TD><TD><I>Exemption from Registration Claimed</I>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">Item 8.</TD><TD><I>Exhibits</I>.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><B>Exhibit  Number</B></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><B>Description of Documents</B></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>3.1</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1840199/000114036122005047/ny20001615x3_f4.htm#tAF">Memorandum and Articles of Association of Waldencast plc, incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on February 14, 2022.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>3.2</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1840199/000114036122016071/ny20001615x19_ex4-5.htm">Specimen Class A Ordinary Share Certificate of Waldencast plc, incorporated by reference to Exhibit 4.5 to the Company's Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on April 27, 2022.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>5.1*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea167276ex5-1_waldencastplc.htm">Opinion of Maples and Calder (Jersey) LLP, Jersey, with respect to the legality of the Class A Ordinary Shares.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="color: Black">23.1*</FONT></TD>
      <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
      <TD><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; color: blue"><FONT STYLE="color: Black"><A HREF="ea167276ex23-1_waldencastplc.htm">Consent of Marcum LLP.</A></FONT></P></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>23.2*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea167276ex23-2_waldencastplc.htm">Consent of Deloitte &amp; Touche LLP, independent registered accounting firm for the Company.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>23.3*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea167276ex23-3_waldencastplc.htm" STYLE="-sec-extract: exhibit">Consent of WithumSmith+Brown, PC.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>23.4*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea167276ex5-1_waldencastplc.htm">Consent of Maples and Calder (Jersey) LLP, Jersey (included in Exhibit 5.1 to this Registration Statement).</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>24.1*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="#sig">Power of Attorney of certain officers and directors (included on the signature page to this Registration Statement).</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>99.1</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1840199/000114036122005047/ny20001615x3_ex10-21.htm">Milk Makeup LLC Appreciation Rights Plan, incorporated by reference to Exhibit 10.21 to the Company&rsquo;s Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on February 14, 2022.</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>99.2</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1840199/000114036122005047/ny20001615x3_ex10-22.htm">Obagi Global Holdings Limited 2021 Stock Incentive Plan, incorporated by reference to Exhibit 10.22 to the Company&rsquo;s Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on February 14, 2022</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>99.3</TD>
      <TD>&nbsp;</TD>
      <TD><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-9_walden.htm">Waldencast plc 2022 Incentive Award Plan, incorporated by reference to Exhibit 4.9 to the Amendment No.1 to the Report on Form 20-F (Reg. No, 001-40207), filed with the SEC on August 3, 2022.</A></P></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>99.4*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea167276ex99-4_waldencastplc.htm">Waldencast plc Incentive Inducement Award Plan</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>107.1*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea167276ex-fee_waldencastplc.htm">Filing Fee Table</A></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"></FONT></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"></FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-weight: normal">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Filed herewith.</FONT></TD>
  </TR></TABLE>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"></FONT></P>
  
  <!-- Field: Page; Sequence: 17; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Item 9.</TD><TD><I>Undertakings</I></TD></TR></TABLE>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-weight: normal">The undersigned registrant hereby
  undertakes: </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">(1) to
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-weight: normal">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">to include any prospectus
  required by Section 10(a)(3) of the Securities Act;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-weight: normal">(ii)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">to reflect in the prospectus
  any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof)
  which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement.
  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
  would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
  reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
  price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
  Fee&rdquo; table in the effective Registration Statement; and</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-weight: normal">(iii)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">to include any material
  information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to
  such information in this Registration Statement.</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">provided, however, that paragraphs
  (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in
  periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act
  that are incorporated by reference in the registration statement; and </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">(2) that,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof; and </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">(3) to
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering. </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">The registrant hereby undertakes
  that, for purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant
  to Sections 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant
  to Section 15(d) of the Securities Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be
  a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof. </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Insofar as indemnification for liabilities
  arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
  provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public
  policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the
  registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
  connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled
  by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
  policy as expressed in the Securities Act and will be governed by the final adjudication of such issue..</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"></FONT></P>
  
  <!-- Field: Page; Sequence: 18; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"></FONT>&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">SIGNATURES</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Pursuant to the requirements of the Securities Act
  of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
  and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
  of White Plains, State of New York, on the 1<SUP>st</SUP> day of November, 2022.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WALDENCAST PLC</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="width: 31%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michel Brousset</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michel Brousset</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sig"></A>POWER OF ATTORNEY AND SIGNATURES </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="background-color: white">KNOW ALL PERSONS
  BY THESE PRESENTS, that each of the undersigned constitutes and appoints Michel Brousset as his or her true and lawful attorneys-in-fact
  and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all
  capacities, to sign this registration statement on Form S-8, or other appropriate form, and all amendments thereto, including post-effective
  amendments, of Waldencast plc, and to file the same, with all exhibits thereto, and other document in connection therewith, with the U.S.
  Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and
  every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might
  or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his or her substitute or substitutes,
  may lawfully do or cause to be done by virtue hereof.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Pursuant to the requirements of the Securities Act
  of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of&nbsp;Capacities</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 23%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Michel Brousset</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">November 1, 2022</P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Michel Brousset</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Executive Officer and<BR>
  Principal Accounting Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Philippe Gautier</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">November 1, 2022</P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Philippe Gautier</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Felipe Dutra</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chairman of the Board of Directors</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">November 1, 2022</P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Felipe Dutra</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Hind Sebti</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Growth Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">November 1, 2022</P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Hind Sebti</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Sarah Brown</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">November 1, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Sarah Brown</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Juliette Hickman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">November 1, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Juliette Hickman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Lindsay Pattison</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">November 1, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Lindsay Pattison</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Cristiano Souza</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">November 1, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Cristiano Souza</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Zack Werner</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">November 1, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Zack Werner</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">November 1, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Simon Dai</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Aaron Chatterley</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">November 1, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Aaron Chatterley</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>
  
  <!-- Field: Page; Sequence: 19; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">AUTHORIZED
  REPRESENTATIVE</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Pursuant to the requirements of the Securities Act
  of 1933, as amended, the undersigned, the duly authorized representative in the United States of Waldencast plc has signed this registration
  statement on November 1, 2022.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WALDENCAST PLC</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="width: 31%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michel Brousset</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michel Brousset</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Person</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-5</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea167276-s8_waldencastplc.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 144371}]
metadata_filer: {"company-data": {"conformed-name": "Waldencast plc", "cik": "0001840199", "assigned-sic": "2844", "irs-number": "000000000"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-268108", "film-number": "221351574"}, "business-address": {"street1": "10 BANK STREET, SUITE 560", "city": "WHITE PLAINS", "state": "NY", "zip": "10606", "phone": "(917) 546-6828"}, "mail-address": {"street1": "10 BANK STREET, SUITE 560", "city": "WHITE PLAINS", "state": "NY", "zip": "10606"}, "former-company": {"former-conformed-name": "Waldencast Acquisition Corp.", "date-changed": "20210112"}}
text: As filed with the Securities and Exchange Commission
  on November 1, 2022
  Registration No. 333-
  UNITED
  STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  Form
  S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  Waldencast
  plc
  (Exact name of
  registrant as specified in its charter)
  Jersey
  Not Applicable
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  10 Bank Street, Suite 560
  White Plains, NY
  10606
  (Address of principal executive offices)
  (Zip code)
  Milk Makeup LLC Appreciation Rights Plan
  Obagi Global Holdings Limited 2021 Stock Incentive
  Plan
  Waldencast plc 2022 Incentive Award Plan
  Waldencast plc Incentive Inducement Award
  Plan
  (Full title of the plans)
  Michel Brousset
  Chief Executive Officer
  c/o Waldencast plc
  10 Bank Street, Suite 560
  White Plains, NY 10606
  (917) 546-6828
  (Name and address, including zip code, and telephone number, including area code, of agent for service)
  Copies to:
  Paul T. Schnell,
  Esq.
  Gregg A. Noel,
  Esq.
  Maxim O. Mayer-Cesiano,
  Esq.
  Michael J. Schwartz,
  Esq.
  Skadden, Arps,
  Slate,
  Meagher &
  Flom LLP
  One Manhattan
  West
  New York, NY
  10001
  Tel: 212-735-3000
  Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
  "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth
  company" in Rule 12b-2 of the Exchange Act. (Check one):
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☐
  Emerging growth company
  ☒
  If an emerging growth company, indicate
  by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  EXPLANATORY NOTE
  This Registration Statement on Form S-8
  (this "Registration Statement") covers the registration of (i) 2,038,112 Class A ordinary shares, par value $0.0001 per
  share ("Class A Ordinary Shares"), of Waldencast plc., a Jersey public limited company (the "Company")
  reserved for issuance under the Milk Makeup LLC Appreciation Rights Plan (the "Milk Plan"); (ii) 7,696,922 Class A
  Ordinary Shares of the Company reserved for issuance under the Obagi Global Holdings Limited 2021 Stock Incentive Plan (the
  "Obagi Plan"); (iii) 16,134,716 Class A Ordinary Shares of the Company reserved for issuance under the Waldencast plc
  2022 Incentive Award Plan (the "Incentive Award Plan"); and (iv) 950,000 Class A Ordinary Shares of the Registrant
  reserved for issuance under the Waldencast plc Incentive Inducement Award Plan (the "Inducement Plan" and together with
  the Milk Plan, the Obagi Plan and the Incentive Award Plan the "Plans"). The Incentive Award Plan has been approved by
  the Company's board of directors and shareholders. The Obagi Plan and the Milk Plan, along with the underlying outstanding
  equity awards (as converted in connection with the Business Combination) and the shares available for issuance under each such plan,
  have been approved and assumed by the Company's board of directors in connection with the closing of the business combination
  between the Company, Obagi Global Holdings Limited, a Cayman Islands exempted company limited by shares ("Obagi"), and
  Milk Makeup LLC, a Delaware limited liability company ("Milk") (such transaction, the "Business
  Combination"). The Inducement Plan has been approved by the Company's board of directors and does not require
  shareholder approval because we are a foreign private issuer and the Inducement Plan provides for incentive awards to individuals,
  who satisfy the standards for "employment inducement" awards under Rule 5635(c)(4) of the Nasdaq Listing Rules, as an
  inducement material to such individuals' entry into employment with the Company.
  This Registration Statement includes a prospectus
  (the "Reoffer Prospectus") prepared in accordance with General Instruction C of Form S-8. This Reoffer Prospectus may be used
  for the reoffer and resale of Class A Ordinary Shares on a continuous or delayed basis that may be deemed to be "control securities"
  within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations promulgated
  thereunder, that are issuable to certain of our executive officers identified in the Reoffer Prospectus. The number of Class A Ordinary
  Shares included in the Reoffer Prospectus represents Class A Ordinary Shares issuable to the selling holders pursuant to the Plans and
  does not necessarily represent a present intention to sell any or all such Class A Ordinary Shares. The number of Class A Ordinary Shares
  to be offered or resold by means of the Reoffer Prospectus by each selling holder, and any other person with whom such holder is acting
  in concert for the purpose of selling Class A Ordinary Shares, may not exceed, during any three-month period, the amount specified in
  Rule 144(e) under the Securities Act.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(A)
  PROSPECTUS
  Item 1.
  Plan Information.
  The document(s) containing the information specified
  in Part I of this Registration Statement will be sent or given to the participants as specified by Rule 428(b)(1) of the Securities Act.
  Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the "SEC"), either
  as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These
  documents, and the documents incorporated by reference herein pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus
  that meets the requirements of Section 10(a) of the Securities Act.
  Item 2.
  Registrant Information and Employee Plan Annual Information
  .
  The written statement required by Item 2 of Part
  I is included in documents that will be delivered to participants in the plans covered by this Registration Statement pursuant to Rule
  428(b) of the Securities Act. In accordance with the rules and regulations of the SEC and the instructions to Form S-8, such documents
  are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to
  Rule 424 under the Securities Act.
  WALDENCAST PLC
  12,462,137 Class A Ordinary Shares Offered by Selling Holders
  This reoffer prospectus ("Reoffer Prospectus")
  relates to the offer and sale from time to time by the selling holders named in this Reoffer Prospectus (the "Selling Holders"),
  or their permitted transferees, of up to 12,462,137 Class A ordinary shares, par value of $0.0001 per share (the "Class A Ordinary
  Shares"), of Waldencast plc., a Jersey public limited company (the "Company"). If, subsequent to the date of this Reoffer
  Prospectus, we grant or deliver additional Class A Ordinary Shares to the Selling Holders or to other affiliates under the Plans, we may
  supplement this Reoffer Prospectus to reflect such additional shares to the Selling Holders and/or the names of such affiliates and the
  number of shares to be reoffered by them under the Plans. We are not offering any Class A Ordinary Shares and will not receive any proceeds
  from the sale of Class A Ordinary Shares by the Selling Holders pursuant to this Reoffer Prospectus. The Selling Holders are certain of
  our executive officers, each of whom may be considered an "affiliate" of our company (as defined in Rule 405 under the Securities
  Act of 1933, as amended (the "Securities Act")).
  Subject to the satisfaction of any conditions
  to vesting of the Class A Ordinary Shares offered hereby pursuant to the terms of the relevant award agreements and the applicable Plan,
  the Selling Holders may from time to time sell, transfer or otherwise dispose of any or all of the Class A Ordinary Shares covered by
  this Reoffer Prospectus through underwriters or dealers, directly to purchasers (or a single purchaser) or through broker-dealers or agents.
  If underwriters or dealers are used to sell the Class A Ordinary Shares, we will name them and describe their compensation in a prospectus
  supplement. The Class A Ordinary Shares may be sold in one or more transactions at fixed prices, prevailing market prices at the time
  of sale, prices related to the prevailing market prices, varying prices determined at the time of sale or negotiated prices. We do not
  know when or in what amount the Selling Holders may offer Class A Ordinary Shares for sale. The Selling Holders may sell any, all or none
  of the Class A Ordinary Shares offered by this Reoffer Prospectus. See "
  Plan of Distribution
  " beginning on page 5
  for more information about how the Selling Holders may sell or dispose of the Class A Ordinary Shares covered by this Reoffer Prospectus.
  The Selling Holders will bear all sales commissions and similar expenses. We will bear all expenses of registration incurred in connection
  with this offering, including any other expenses incurred by us in connection with the registration and offering that are not borne by
  the Selling Holders.
  The Class A Ordinary Shares that will be issued
  pursuant to restricted stock units, stock appreciation rights and stock options granted to Selling Holders will be "control securities"
  under the Securities Act before their sale under this Reoffer Prospectus. This Reoffer Prospectus has been prepared for the purposes of
  registering the Class A Ordinary Shares under the Securities Act to allow for future sales by Selling Holders on a continuous or delayed
  basis to the public without restriction, provided that the number of Class A Ordinary Shares to be offered or resold under this Reoffer
  Prospectus by each Selling Holder or other person with whom he, she or they are acting in concert for the purpose of selling Class A Ordinary
  Shares, may not exceed, during any three-month period, the amount specified in Rule 144(e) under the Securities Act.
  Our Class A Ordinary Shares are currently listed on
  The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "WALD." On October 31, 2022, the last reported sales price
  of the Class A Ordinary Shares on Nasdaq was $8.90 per share.
  We are an "emerging growth company,"
  as defined under the federal securities laws, and, as such, have elected to comply with certain reduced public company reporting requirements
  for this Reoffer Prospectus and for future filings.
  INVESTING IN OUR SECURITIES INVOLVES RISKS
  THAT ARE DESCRIBED IN THE "RISK FACTORS" SECTION BEGINNING ON PAGE 3 OF THIS REOFFER PROSPECTUS, AND SUCH RISKS AND THE
  "CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS" ON PAGE v OF THIS REOFFER PROSPECTUS SHOULD BE REVIEWED CAREFULLY.
  Neither the Securities and Exchange Commission
  nor any state securities commission has approved or disapproved of the securities to be issued under this Reoffer Prospectus or determined
  if this Reoffer Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
  The date of this Reoffer Prospectus is November
  1, 2022
  TABLE OF CONTENTS
  ABOUT THIS REOFFER PROSPECTUS
  ii
  WHERE YOU CAN FIND MORE INFORMATION
  iii
  INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
  iv
  CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
  v
  SUMMARY OF THE PROSPECTUS
  1
  RISK FACTORS
  3
  DETERMINATION OF OFFERING PRICE
  3
  USE OF PROCEEDS
  3
  SELLING HOLDERS
  4
  PLAN OF DISTRIBUTION
  5
  LEGAL MATTERS
  6
  EXPERTS
  6
  You should rely only on the information contained
  in this Reoffer Prospectus. No one has been authorized to provide you with information that is different from that contained in this Reoffer
  Prospectus. If anyone provides you with different or inconsistent information, you should not rely on it.
  For investors outside the United States:
  We
  have not done anything that would permit this offering or possession or distribution of this Reoffer Prospectus in any jurisdiction where
  action for that purpose is required, other than in the United States. You are required to inform yourselves about, and to observe, any
  restrictions relating to this offering and the distribution of this Reoffer Prospectus.
  i
  ABOUT
  THIS REOFFER PROSPECTUS
  This Reoffer Prospectus contains important information
  you should know before investing, including important information about the Company and the securities being offered. You should carefully
  read this Reoffer Prospectus, as well as the additional information contained in the documents described under "
  Where You Can
  Find More Information
  " and "
  Incorporation of Certain Information by Reference
  " in this Reoffer Prospectus,
  and in particular the periodic and current reporting documents we file with the Securities and Exchange Commission (the "SEC").
  This Reoffer Prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction
  where the offer or sale is not permitted.
  This Reoffer Prospectus is dated as of the date
  set forth on the cover hereof. You should not assume that the information contained in this Reoffer Prospectus is accurate as of any date
  other than that date or as of any earlier date specified, including in any information incorporated by reference. Our business, financial
  condition, results of operations and prospects may have changed since those dates.
  The Jersey Financial Services Commission ("JFSC")
  has given and has not withdrawn, its consent under Article 4 of the Control of Borrowing (Jersey) Order 1958 to the issue of securities
  in the Issuer. The JFSC is protected by the Control of Borrowing (Jersey) Law 1947, as amended, against liability arising from the discharge
  of its functions under that Law.
  A copy of this prospectus has been delivered to
  the Jersey Registrar of Companies (the "Jersey Registrar") in accordance with Article 5 of the Companies (General Provisions)
  (Jersey) Order 2002 and the Jersey Registrar has given, and has not withdrawn, his consent to its circulation. It must be distinctly understood
  that, in giving these consents, neither the Jersey Registrar nor the JFSC takes any responsibility for the financial soundness of the
  Company or for the correctness of any statements made, or opinions expressed, with regard to it. The JFSC is protected by the Control
  of Borrowing (Jersey) Law 1947, as amended, against liability arising from the discharge of its functions under that law. The directors
  of the Company have taken all reasonable care to ensure that the facts stated in this prospectus are true and accurate in all material
  respects, and that there are no other facts the omission of which would make misleading any statement in the document, whether or facts
  or of opinion. The directors accept responsibility accordingly. It should be remembered that the price of securities and the income from
  them can go down as well as up. If you are in any doubt about the contents of this prospectus, you should consult your stockbroker, bank
  manager, solicitor, accountant or financial adviser.
  ii
  WHERE
  YOU CAN FIND MORE INFORMATION
  We have filed a Registration Statement on Form
  S-8 (this "Registration Statement"), including exhibits, under the Securities Act, with respect to the Class A Ordinary Shares
  offered by this Reoffer Prospectus. This Reoffer Prospectus does not contain all of the information included in this Registration Statement.
  For further information pertaining to us and our securities, you should refer to this Registration Statement and its exhibits.
  We are subject to the informational requirements
  of the Securities Exchange Act of 1934, as amended (the "Exchange Act") that are applicable to foreign private issuers. Accordingly,
  we are required to file or furnish reports and other information with the SEC, including annual reports on Form 20-F and reports on Form
  6-K. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with
  the SEC. Our filings with the SEC are available to the public through the SEC's website at http://www.sec.gov.
  As a foreign private issuer, we are exempt under
  the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers,
  directors and principal and Selling Securityholders are exempt from the reporting and short-swing profit recovery provisions contained
  in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial
  statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.
  We maintain a corporate website at www.waldencast.com.
  Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included
  our website address in this prospectus solely for informational purposes.
  iii
  INCORPORATION
  OF CERTAIN INFORMATION BY REFERENCE
  The following documents, previously filed by the
  Company with the SEC, are incorporated by reference in this Registration Statement of which this Reoffer Prospectus forms a part:
  (i)
  The Company's prospectus relating to the Registration Statement on Form F-1, as amended (File No. 333-267053), filed with the
  SEC under Rule
  424(b)
  under the Securities Act on October 13, 2022, which contains, inter alia, the audited financial statements of the
  Company for the latest fiscal year for which such statements have been filed; and
  (ii)
  The description of the Company's Class A Ordinary Shares contained in the Company's Registration Statement on
  Form F-4
  , as amended (File No. 333-262692) filed with the SEC on February 14, 2022, including any amendments or reports filed for the purpose of updating such description.
  All reports and other documents subsequently filed
  by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement of which
  this Reoffer Prospectus forms a part, but prior to the filing of a post-effective amendment which indicates that all securities offered
  hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein
  and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been
  furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Reoffer Prospectus.
  Any statement contained herein or in a document,
  all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this Reoffer Prospectus to the extent that a statement contained herein or in any other subsequently filed document which
  also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute a part of this Reoffer Prospectus.
  The Company undertakes to provide without charge
  to each person, including any beneficial owner, to whom a copy of this Reoffer Prospectus is delivered, upon written or oral request of
  any such person, a copy of any and all of the information that has been incorporated by reference in this Reoffer Prospectus but not delivered
  with this Reoffer Prospectus other than the exhibits to those documents, unless the exhibits are specifically incorporated by reference
  into the information that this Reoffer Prospectus incorporates. Documents incorporated by reference in this Reoffer Prospectus may be
  obtained by requesting them in writing or by telephone from us at:
  Waldencast plc
  10 Bank Street, Suite 560
  White Plains, NY 10606
  Telephone: (917) 546-6828
  iv
  CAUTIONARY
  STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
  Certain statements made in this Reoffer Prospectus
  are "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act,
  and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements
  provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations,
  beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words such as "estimates,"
  "projected," "expects," "estimated," "anticipates," "suggests," "projects,"
  "forecasts," "plans," "intends," "believes," "seeks," "may," "will,"
  "would," "should," "could," "future," "propose," "target," "goal,"
  "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such
  words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future
  performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors,
  many of which are outside our control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
  statements. Important factors, among others, that may affect actual results or outcomes include:
  ●
  our inability to recognize the anticipated benefits of the transactions with Obagi and Milk;
  ●
  changes in general economic conditions, including as a result of the COVID-19 pandemic;
  ●
  our ability to continue to meet Nasdaq's listing standards;
  ●
  volatility of our securities due to a variety of factors, including our inability to meet or exceed our financial projections and
  changes;
  ●
  our ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities;
  ●
  our ability to implement strategic initiatives and continue to innovate Obagi's and Milk's existing products and anticipate
  and respond to market trends and changes in consumer preferences; and
  ●
  other factors detailed in the section entitled "Risk Factors."
  The forward-looking statements contained in this
  Reoffer Prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us.
  There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements
  involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or
  performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties
  include, but are not limited to, those factors described under the heading "
  Risk Factors
  " in this Reoffer Prospectus.
  Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary
  in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking
  statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities
  laws.
  v
  SUMMARY
  OF THE PROSPECTUS
  This Reoffer Prospectus is part of this Registration
  Statement that we filed with the SEC. We have provided to you in this Reoffer Prospectus a general description of the Selling Holders
  and the distribution of the Class A Ordinary Shares. To the extent there is a conflict between the information contained in this Reoffer
  Prospectus and any of our subsequent filings with the SEC, the information in the document having the later date shall modify or supersede
  the earlier statement.
  As permitted by the rules and regulations of
  the SEC, this Registration Statement of which this Reoffer Prospectus forms a part includes additional information not contained in this
  Reoffer Prospectus. You may read this Registration Statement and the other reports we file with the SEC at the SEC's website or
  at our website as described above under the heading "Incorporation of Certain Information by Reference."
  As used in this Reoffer Prospectus, unless
  the context otherwise requires or indicates, references to "we," "us," "our," and the "Company"
  refer to Waldencast plc and its consolidated subsidiaries.
  Company Overview
  Founded by Michel Brousset and Hind Sebti, our
  ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling
  conscious, high-growth purpose-driven brands. Our vision is fundamentally underpinned by our brand-led business model that ensures proximity
  to our customers, business agility and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing
  our vision was the business combination with Obagi and Milk. As part of the Waldencast platform, our brands will benefit from the operational
  scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations;
  asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands.
  We were incorporated on December 8, 2020 as a
  Cayman Islands exempted company and a blank check company solely for the purpose of effecting the Business Combination, which was consummated
  on July 27, 2022. On July 26, 2022, with the approval of our shareholders, and in accordance with the Cayman Act, the Jersey Companies
  Law and our memorandum and articles of association, we effected a domestication, pursuant to which our jurisdiction of incorporation was
  changed from the Cayman Islands to Jersey and our name was changed from Waldencast Acquisition Corp. to Waldencast plc, a public limited
  company incorporated under the laws of Jersey. Upon the closing of the Business Combination, we acquired the businesses of Obagi and Milk,
  which are now indirect subsidiaries of Waldencast.
  Our Professional Skincare Segment: Obagi
  Our professional skincare segment consists of
  the Obagi business. Obagi is currently headquartered in Long Beach, California, but will begin operating out of new headquarters in Houston,
  Texas in the fourth quarter of 2022. Obagi is a pioneer of the professional skincare category and its products are rooted in research
  and skin biology. Obagi develops, markets and sells innovative skin health products in more than 60 countries around the world. The Obagi®
  collection of products includes the following brands, with more than 200 products sold throughout the medical, spa and retail channels:
  Obagi Medical®, Obagi Clinical® and Skintrinsiq™. While the product portfolio consists predominantly of cosmetic and over-the-counter
  ("OTC") drug products, Obagi does offer prescription-strength drug products, which require approval from the U.S. Food and
  Drug Administration (the "FDA") prior to marketing. We have not sought or obtained FDA pre-market approval or foreign regulatory
  authorities' authorization for any Obagi products, including the Skintrinsiq device, which we believe does not require marketing
  authorization from the FDA. These prescription-strength products include the Obagi Nu-Derm® System and related products, some of which
  contain a 4% concentration of the ingredient hydroquinone ("HQ"). These products are marketed as prescription-use only drugs
  but have not received marketing authorization from the FDA or other regulatory authorities. The FDA has historically utilized a risk-based
  enforcement approach with respect to drugs marketed without the required New Drug Application ("NDA") in accordance with a
  Compliance Policy Guide ("CPG") it issued in 2006 and subsequently amended in 2011, in which the FDA announced a drug safety
  initiative to remove unapproved drugs from the market, and established enforcement priorities and a policy of enforcement discretion with
  respect to marketed unapproved products. We believe Obagi's prescription-only HQ products do not fall within the categories of unapproved
  drugs for which the FDA has indicated it prioritizes enforcement. We have not received any communications from the FDA or any similar
  regulatory authorities regarding its HQ or any of its other products. However, whether due to safety concerns or otherwise, in the future
  the FDA may choose to pursue an enforcement action against us and determine that Obagi HQ products should be removed from the market until
  we obtain FDA approval of the required NDA. Although Obagi prescription-only HQ products are made with 4% HQ, the FDA has historically
  expressed concerns regarding the safety of 2% HQ products sold on an OTC basis. In addition, the CARES Act implemented a number of changes
  to regulation of OTC drugs, one of which prohibited the sale of HQ (at any concentration level) from being marked in the U.S. as an OTC
  drug without FDA approval effective September 2020. On April 19, 2022, the FDA announced that it had issued warning letters to 12 companies
  for continuing to sell 2% HQ products on an OTC basis in violation of the CARES Act. The FDA's announcement also cited reports describing
  serious side effects associated with the use of skin lightening products containing HQ, including reports of skin rashes, facial swelling,
  and ochronosis (discoloration of the skin). The FDA's safety concerns regarding these lower-concentration OTC HQ products could
  prompt the FDA to assert that Obagi's higher-concentration, prescription-only HQ products represent a higher priority for enforcement
  pursuant to the active CPG. In addition, Obagi's prescription-only products are not currently available in pharmacies. Certain states,
  including Massachusetts, Montana, New Hampshire, New York and Texas, prohibit physicians from dispensing prescription products without
  a pharmacy or other license or authorization, permitting dispensing of such products only in certain limited circumstances. For these
  states we offer alternate products under our Obagi Nu-Derm Fx® and Obagi-C® Fx product lines that contain the skin brightening
  ingredient arbutin rather than 4% HQ. Further, we are aware that the state of Texas and Puerto Rico, as well as certain credit card authorization
  vendors, have taken action against physician customers who sell Obagi's prescription products to patients over the Internet. Most
  of these physicians ceased selling the prescription products online, offering them only in office to patients, and/or chose to sell Obagi's
  alternate arbutin products online instead. These actions have not had a material impact on our or Obagi's sales or net revenue.
  1
  Our "Clean" Makeup Segment: Milk
  Our "clean" makeup segment consists
  of the Milk business. Milk is a leading, award-winning clean prestige makeup brand with unique products, a dedicated following among Gen-Z
  consumers and an emerging global presence. Milk has achieved significant growth thus far but believes even more significant growth opportunities
  remain in terms of building awareness, product and category expansion, channel expansion and regional expansion.
  We believe that Milk's inclusive brand values,
  "clean" product philosophy and commitments to sustainability and philanthropy are at the zeitgeist of what will motivate the
  next generation of beauty consumers around the world, and that these values and product attributes will only become more relevant. We
  believe that Milk's ability to authentically connect with youth culture while developing unique, effective and easy to use products
  that are also 100% vegan, clean and cruelty-free sets Milk apart from other brands.
  Milk was launched in 2016 with the goal of building
  a global movement to challenge and broaden the definition of beauty. Community and self-expression are at the heart of everything Milk
  does, believing that it's not how you wear your makeup, it's what you do in it that matters. This ethos is captured in Milk's
  brand signature, "Live Your Look."
  The Offering
  This Reoffer Prospectus relates to the offer and
  sale from time to time by the Selling Holders, or their permitted transferees, of up to 12,462,137 Class A Ordinary Shares. If, subsequent
  to the date of this Reoffer Prospectus, we grant additional Class A Ordinary Shares to the Selling Holders or to other affiliates under
  the Plans, we may supplement this Reoffer Prospectus to reflect such additional shares to the Selling Holders and/or the names of such
  affiliates and the number of shares to be reoffered by them under the Plans. Subject to the satisfaction of any conditions to vesting
  of the Class A Ordinary Shares offered hereby pursuant to the terms of the relevant award agreements, the Selling Holders may from time
  to time sell, transfer or otherwise dispose of any or all of the Class A Ordinary Shares covered by this Reoffer Prospectus through underwriters
  or dealers, directly to purchasers (or a single purchaser) or through broker-dealers or agents. We will not receive any proceeds from
  the sale of Class A Ordinary Shares by the Selling Holders. The Selling Holders will bear all sales commissions and similar expenses.
  We will bear all expenses of registration incurred in connection with this offering, including any other expenses incurred by us in connection
  with the registration and offering that are not borne by the Selling Holders.
  2
  RISK
  FACTORS
  Investing in Class A Ordinary Shares involves
  a high degree of risk. Investors should carefully consider the risks we have described under "Risk Factors" in our prospectus
  relating to the Registration Statement on Form F-1, as amended (File No. 333-267053), filed with the SEC under Rule
  424(b)
  under the Securities
  Act on October 13, 2022, together with all the other information appearing in or incorporated by reference into this Reoffer Prospectus,
  before deciding to invest in our Class A Ordinary Shares. If any of the events or developments we have described occur, our business,
  financial condition, or results of operations could be materially or adversely affected. As a result, the market price of our Class A
  Ordinary Shares could decline, and investors could lose all or part of their investment. The risks and uncertainties we have described
  are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that we currently
  deem immaterial may also impair our business operations. The risks we have described also include forward-looking statements, and our
  actual results may differ substantially from those discussed in these forward-looking statements. See "
  Cautionary Statement Regarding
  Forward-Looking Statements
  ."
  DETERMINATION
  OF OFFERING PRICE
  The Selling Holders will determine at what price
  they may sell the offered Class A Ordinary Shares, and such sales may be made at prevailing market prices or at privately negotiated prices.
  See "
  Plan of Distribution
  " below for more information.
  USE
  OF PROCEEDS
  We will not receive any proceeds from the sale
  of the Class A Ordinary Shares by the Selling Holders.
  3
  SELLING
  HOLDERS
  The table below sets forth information concerning
  the resale of the Class A Ordinary Shares by the Selling Holders. We will not receive any proceeds from the resale of the Class A Ordinary
  Shares by the Selling Holders.
  The table below sets forth, as of October 1,
  2022 (the "Determination Date"): (i) the name of each person who is offering the resale of Class A Ordinary Shares by this
  Reoffer Prospectus; (ii) the number of Class A Ordinary Shares that each Selling Holder may offer for sale from time to time pursuant
  to this Reoffer Prospectus, whether or not such Selling Holder has a present intention to do so; and (iii) the number (and the percentage,
  if 1% or more) of Class A Ordinary Shares each person will own after the offering, assuming they sell all of the shares offered. Unless
  otherwise indicated, beneficial ownership is direct and the person indicated has sole voting and investment power. Unless otherwise indicated,
  the address for each Selling Holder listed in the table below is c/o Waldencast plc., 10 Bank Street, Suite 560, White Plains, NY 10606.
  The Selling Holders identified below may have
  sold, transferred or otherwise disposed of some or all of their Class A Ordinary Shares since the date on which the information in the
  following table is presented in transactions exempt from or not subject to the registration requirements of the Securities Act. Information
  concerning the Selling Holders may change from time to time and, if necessary, we will amend or supplement this Reoffer Prospectus accordingly.
  We cannot give an estimate as to the number of Class A Ordinary Shares that will actually be held by the Selling Holders upon termination
  of this offering because the Selling Holders may offer some or all of their Class A Ordinary Shares under the offering contemplated by
  this Reoffer Prospectus or acquire additional Class A Ordinary Shares. The total number of Class A Ordinary Shares that may be sold hereunder
  will not exceed the number of Class A Ordinary Shares offered hereby. Please read the section entitled "
  Plan of Distribution
  "
  in this Reoffer Prospectus.
  Selling
      Holder
  Position
      with Company
  Class
      A Ordinary Shares Beneficially Owned Prior
  to this
  Offering (1) (2)
  Class
      A Ordinary Shares Offered for Resale
  in this
  Offering (2)
  Class
      A Ordinary Shares Beneficially Owned
  After this
  Offering (3)
  Percentage
  of Class A
  Ordinary
  Shares
  Beneficially
  Owned
  After this
  Offering (1)(3)
  Michel Brousset
  (4)
  Chief Executive Officer and Director
  14,109,447
  8,950,000
  5,159,447
  5.8
  %
  Hind Sebti
  Chief Growth Officer
  3,502,000
  3,502,000
  —
  —
  Philippe Gautier
  Chief Financial Officer and
  Chief Operating Officer
  10,137
  10,137
  —
  —
  *
  Less than 1%
  (1)
  Beneficial ownership and the percentage of Class A Ordinary Shares beneficially owned is computed on the basis of 86,460,560 Class
  A Ordinary Shares outstanding as of the Determination Date and determined in accordance with the rules and regulations of the SEC.
  (2)
  Includes Class A Ordinary Shares issuable upon settlement of restricted stock units and stock options, including those that will vest
  more than 60 days from the Determination Date.
  (3)
  Assumes that all of the Class A Ordinary Shares held by each Selling Holder and being offered under this Reoffer Prospectus are sold, and that no Selling Holder will acquire additional Class A Ordinary Shares before the completion of this offering.
  (4)
  Includes (i) 2,848,334 Class A ordinary shares, (ii) 1,977,779 Class A ordinary shares issuable upon exercise of the private placement warrants and (iii) 333,334 Class A ordinary shares issuable upon exercise of the working capital loan warrants, held by Waldencast Ventures, LP. Mr. Brousset is the chief executive officer of Waldencast Management, LLC, the general partner of Waldencast Ventures, LP. As such, he may be deemed to beneficially own the shares held by Waldencast Ventures, LP.
  4
  PLAN
  OF DISTRIBUTION
  The Class A Ordinary Shares covered by this Reoffer
  Prospectus are being registered by the Company for the account of the Selling Holders. The Class A Ordinary Shares offered may be sold
  from time to time directly by or on behalf of each Selling Holder in one or more transactions on Nasdaq or any other stock exchange on
  which the Class A Ordinary Shares may be listed at the time of sale, in privately negotiated transactions, or through a combination of
  such methods, at market prices prevailing at the time of sale, at prices related to such prevailing market prices, at fixed prices (which
  may be changed) or at negotiated prices. The Selling Holders may from time to time sell, transfer or otherwise dispose of any or all of
  the Class A Ordinary Shares covered by this Reoffer Prospectus through underwriters or dealers, directly to purchasers (or a single purchaser)
  or through broker-dealers or agents. Such underwriters or dealers may receive compensation in the form of commissions, discounts or concessions
  from the Selling Holders and/or purchasers of the shares or both. Such compensation as to a particular underwriter, broker or dealer may
  be in excess of customary commissions. The number of Class A Ordinary Shares to be reoffered or resold under the Reoffer Prospectus by
  each Selling Holder and any other person with whom he, she or they is acting in concert for the purpose of selling Class A Ordinary Shares,
  may not exceed, during any three-month period, the amount specified in Rule 144(e) under the Securities Act.
  In connection with their sales, a Selling Holder
  and any participating underwriter or dealer may be deemed to be "underwriters" within the meaning of the Securities Act, and
  any commissions they receive and the proceeds of any sale of shares may be deemed to be underwriting discounts and commissions under the
  Securities Act. We are bearing all costs relating to the registration of the Class A Ordinary Shares. Any commissions or other fees payable
  to underwriters or dealers in connection with any sale of the shares will be borne by the Selling Holders or other party selling such
  shares. Sales of the Class A Ordinary Shares must be made by the Selling Holders in compliance with all applicable state and federal securities
  laws and regulations, including the Securities Act. In addition to any shares sold hereunder, Selling Holders may sell Class A Ordinary
  Shares in compliance with Rule 144, if available. There is no assurance that the Selling Holders will sell all or a portion of the Class
  A Ordinary Shares offered hereby. The Selling Holders may agree to indemnify any underwriter, broker, dealer or agent that participates
  in transactions involving sales of the Class A Ordinary Shares against certain liabilities in connection with the offering of the Class
  A Ordinary Shares arising under the Securities Act. We have notified the Selling Holders of the need to deliver a copy of this Reoffer
  Prospectus in connection with any sale of the Class A Ordinary Shares.
  The anti-manipulation rules of Regulation M under
  the Exchange Act may apply to sales of Class A Ordinary Shares and activities of the Selling Holders, which may limit the timing of purchases
  and sales of any of the Class A Ordinary Shares by the Selling Holders and any other participating person. Regulation M may also restrict
  the ability of any person engaged in the distribution of the Class A Ordinary Shares to engage in passive market-making activities with
  respect to the Class A Ordinary Shares. Passive market making involves transactions in which a market maker acts as both our underwriter
  and as a purchaser of Class A Ordinary Shares in the secondary market. All of the foregoing may affect the marketability of the Class
  A Ordinary Shares and the ability of any person or entity to engage in market-making activities with respect to the Class A Ordinary Shares.
  Once sold under the registration statement of
  which this Reoffer Prospectus forms a part, the Class A Ordinary Shares will be freely tradable in the hands of persons other than our
  affiliates.
  5
  LEGAL
  MATTERS
  The validity of the securities offered hereby
  will be passed upon for us by Maples and Calder (Jersey) LLP, Jersey counsel to the Company.
  EXPERTS
  The financial statements of Waldencast Acquisition
  Corp. as of December 31, 2021 and 2020, and for the year ended December 31, 2021 and for the period from December 8, 2020 (inception)
  through December 31, 2020, incorporated by reference in this prospectus have been audited by Marcum LLP, an independent registered public
  accounting firm, as stated in their report incorporated by reference herein, which includes an explanatory paragraph as to the company's
  ability to continue as a going concern. Such financial statements are incorporated by reference in reliance upon the report of such firm
  given upon their authority as experts in accounting and auditing.
  The consolidated financial statements of Obagi
  Global Holdings Limited as of December 31, 2021 and December 31, 2020 and for each of the three years in the period ended December 31,
  2021 incorporated by reference in this prospectus, have been audited by Deloitte & Touche LLP, an independent registered public accounting
  firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given
  their authority as experts in accounting and auditing.
  The financial statements of Milk Makeup LLC as
  of December 31, 2021, 2020 and 2019, and for each of the three years then ended incorporated by reference in this prospectus have been
  incorporated by reference herein in reliance upon the report of WithumSmith+Brown, PC, independent registered public accounting firm,
  incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.
  6
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3.
  Incorporation of Documents by Reference
  .
  The following documents, previously filed by the
  Company with the SEC, are incorporated by reference in this Registration Statement:
  (i)
  The Company's prospectus relating to the Registration Statement on Form F-1, as amended (File No. 333-267053), filed with the
  SEC under Rule
  424(b)
  under the Securities Act on October 13, 2022, which contains, inter alia, the audited financial statements of the
  Company for the latest fiscal year for which such statements have been filed; and
  (ii)
  The description of the Company's Class A Ordinary Shares contained in the Company's Registration Statement on
  Form F-4
  , as amended (File No. 333-262692) filed with the SEC on February 14, 2022, including any amendments or reports filed for the purpose of updating such description.
  All reports and other documents filed by the Company
  pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of this Registration Statement, but prior to the filing
  of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then
  remaining unsold, shall be deemed to be incorporated by reference in herein and to be a part hereof from the date of filing of such documents;
  provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall
  not be deemed incorporated by reference into this Registration Statement.
  Any statement contained herein or in a document,
  all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded
  for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document
  which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified
  or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
  Item 4.
  Description of Securities
  .
  Not applicable.
  Item 5.
  Interests of Named Experts and Counsel
  .
  Not applicable.
  Item 6.
  Indemnification of Directors and Officers
  .
  Subject to the Jersey
  Companies Law, our articles of association (the "Articles") permit us (to the fullest extent permitted by the Jersey Companies
  Law to indemnify any director against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses,
  which they may incur as a result of any act or failure to act in carrying out their functions. However this does not apply if such liability
  incurred by reason of their own actual fraud, willful neglect or willful default. Subject to the Jersey Companies Law, our Articles also
  permit us to purchase and maintain insurance against any liability for any director and to provide any director with funds (whether by
  loan or otherwise) to meet expenditure incurred or to be incurred by him in defending any criminal, regulatory or civil proceedings or
  in connection with an application for relief (or to enable any such director to avoid incurring such expenditure).
  II-
  1
  However, Article 77 of
  the Jersey Companies Law limits the ability of a Jersey company to exempt or indemnify a director from any liability arising from acting
  as a director. It provides that neither a company (or any of its subsidiaries) nor any other person for some benefit conferred or detriment
  suffered directly or indirectly by the company, may exempt or indemnify any director from, or against, any liability incurred by him as
  a result of being a director of the company except where the company exempts or indemnifies him against:
  a)
  any liabilities incurred in defending any proceedings (whether civil or criminal):
  i)
  in which judgment is given in his or her favor or he or she is acquitted;
  ii)
  which are discontinued otherwise than for some benefit conferred by him or her or on his or her behalf or some detriment suffered
  by him or her; or
  iii)
  which are settled on terms which include such benefit or detriment and, in the opinion of a majority of the directors of the company
  (excluding any director who conferred such benefit or on whose behalf such benefit was conferred or who suffered such detriment), he or
  she was substantially successful on the merits in his or her resistance to the proceedings; or
  b)
  any liability incurred otherwise than to the company if he or she acted in good faith with a view to the best interests of the company;
  c)
  any liability incurred in connection with an application made under Article 212 of the Jersey Companies Law in which relief is granted
  to him or her by the court; or
  d)
  any liability against which the company normally maintains insurance for persons other than directors.
  Article 77 of the Jersey Companies Law does not
  prevent a company from purchasing and maintaining directors' and officers' insurance and we maintain a directors' and
  officers' liability insurance policy for the benefit of our directors and officers.
  Item 7.
  Exemption from Registration Claimed
  .
  Not applicable.
  Item 8.
  Exhibits
  .
  Exhibit  Number
  Description of Documents
  3.1
  Memorandum and Articles of Association of Waldencast plc, incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on February 14, 2022.
  3.2
  Specimen Class A Ordinary Share Certificate of Waldencast plc, incorporated by reference to Exhibit 4.5 to the Company's Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on April 27, 2022.
  5.1*
  Opinion of Maples and Calder (Jersey) LLP, Jersey, with respect to the legality of the Class A Ordinary Shares.
  23.1*
  Consent of Marcum LLP.
  23.2*
  Consent of Deloitte & Touche LLP, independent registered accounting firm for the Company.
  23.3*
  Consent of WithumSmith+Brown, PC.
  23.4*
  Consent of Maples and Calder (Jersey) LLP, Jersey (included in Exhibit 5.1 to this Registration Statement).
  24.1*
  Power of Attorney of certain officers and directors (included on the signature page to this Registration Statement).
  99.1
  Milk Makeup LLC Appreciation Rights Plan, incorporated by reference to Exhibit 10.21 to the Company's Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on February 14, 2022.
  99.2
  Obagi Global Holdings Limited 2021 Stock Incentive Plan, incorporated by reference to Exhibit 10.22 to the Company's Registration Statement on Form F-4 (File No. 333-262692), as amended, filed with the SEC on February 14, 2022
  99.3
  Waldencast plc 2022 Incentive Award Plan, incorporated by reference to Exhibit 4.9 to the Amendment No.1 to the Report on Form 20-F (Reg. No, 001-40207), filed with the SEC on August 3, 2022.
  99.4*
  Waldencast plc Incentive Inducement Award Plan
  107.1*
  Filing Fee Table
  *
  Filed herewith.
  II-
  2
  Item 9.
  Undertakings
  The undersigned registrant hereby
  undertakes:
  (1) to
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  to include any prospectus
  required by Section 10(a)(3) of the Securities Act;
  (ii)
  to reflect in the prospectus
  any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof)
  which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement.
  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
  would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
  reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
  price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration
  Fee" table in the effective Registration Statement; and
  (iii)
  to include any material
  information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to
  such information in this Registration Statement.
  provided, however, that paragraphs
  (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in
  periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act
  that are incorporated by reference in the registration statement; and
  (2) that,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof; and
  (3) to
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.
  The registrant hereby undertakes
  that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant
  to Sections 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant
  to Section 15(d) of the Securities Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be
  a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof.
  Insofar as indemnification for liabilities
  arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
  provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public
  policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the
  registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
  connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled
  by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
  policy as expressed in the Securities Act and will be governed by the final adjudication of such issue..
  II-
  3
  SIGNATURES
  Pursuant to the requirements of the Securities Act
  of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
  and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
  of White Plains, State of New York, on the 1
  st
  day of November, 2022.
  WALDENCAST PLC
  By:
  /s/ Michel Brousset
  Name:
  Michel Brousset
  Title:
  Chief Executive Officer
  POWER OF ATTORNEY AND SIGNATURES
  KNOW ALL PERSONS
  BY THESE PRESENTS, that each of the undersigned constitutes and appoints Michel Brousset as his or her true and lawful attorneys-in-fact
  and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all
  capacities, to sign this registration statement on Form S-8, or other appropriate form, and all amendments thereto, including post-effective
  amendments, of Waldencast plc, and to file the same, with all exhibits thereto, and other document in connection therewith, with the U.S.
  Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and
  every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might
  or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his or her substitute or substitutes,
  may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements of the Securities Act
  of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
  Signature
  Title of Capacities
  Date
  /s/ Michel Brousset
  Chief Executive Officer and Director
  November 1, 2022
  Michel Brousset
  (Principal Executive Officer and
  Principal Accounting Officer)
  /s/ Philippe Gautier
  Chief Financial Officer and Chief Operating Officer
  November 1, 2022
  Philippe Gautier
  (Principal Financial Officer)
  /s/ Felipe Dutra
  Chairman of the Board of Directors
  November 1, 2022
  Felipe Dutra
  /s/ Hind Sebti
  Chief Growth Officer
  November 1, 2022
  Hind Sebti
  /s/ Sarah Brown
  Director
  November 1, 2022
  Sarah Brown
  /s/ Juliette Hickman
  Director
  November 1, 2022
  Juliette Hickman
  /s/ Lindsay Pattison
  Director
  November 1, 2022
  Lindsay Pattison
  /s/ Cristiano Souza
  Director
  November 1, 2022
  Cristiano Souza
  /s/ Zack Werner
  Director
  November 1, 2022
  Zack Werner
  Director
  November 1, 2022
  Simon Dai
  /s/ Aaron Chatterley
  Director
  November 1, 2022
  Aaron Chatterley
  II-
  4
  AUTHORIZED
  REPRESENTATIVE
  Pursuant to the requirements of the Securities Act
  of 1933, as amended, the undersigned, the duly authorized representative in the United States of Waldencast plc has signed this registration
  statement on November 1, 2022.
  WALDENCAST PLC
  By:
  /s/ Michel Brousset
  Name:
  Michel Brousset
  Title:
  Authorized Person
  II-5